Meeting
2022 ASCO Annual Meeting
Oral azacitidine plus venetoclax in patients with relapsed/refractory or newly diagnosed acute myeloid leukemia: The phase 1b OMNIVERSE trial.
Authors
Farhad Ravandi
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
Farhad Ravandi , Hetty E Carraway , Lilia Taningco , Eric Laille , Jing Gong , Thomas Prebet , Daniel Lopes de Menezes , Andrew H. Wei
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Track
Hematologic Malignancies
Sub Track
Acute Leukemia
Clinical Trial Registration Number
NCT04887857
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr TPS7068)
DOI
10.1200/JCO.2022.40.16_suppl.TPS7068
Abstract #
TPS7068
Poster Bd #
296b
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
An international phase 3 randomized, placebo-controlled study of CC-486 (oral azacitidine) maintenance therapy in patients with acute myeloid leukemia (AML) in complete remission (CR): The Quazar AML maintenance trial.
First Author: Gail J. Roboz
Poster
2024 ASCO Annual Meeting
A prospective study of all-trans retinoic acid plus venetoclax and azacitidine in newly diagnosed acute myeloid leukemia.
First Author: Chengyuan Gu
Poster
2023 ASCO Breakthrough
Survival benefit of maintenance therapy in AML patients after complete remission in northeast Iran oncology centers with limited access to oral azacitidine.
First Author: Somayeh Sadat Shariatmaghani
Poster
2022 ASCO Annual Meeting
Efficacy and safety of venetoclax in combination with azacitidine or decitabine in an outpatient setting in patients with untreated acute myeloid leukemia.
First Author: Sudhir Manda